MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (9)

Houston, Texas 77030-4009

0 studies enrolling now · 1 studies all time

What they study most

Symptomatic Refractory Resistant Carcinoid Disease

Studies at this site

• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease — Completed